TAGCyx announces a research collaboration with CAGE Bio Inc. for autoimmune skin diseases.
TAGCyx biotechnologies Inc. announced entering into a research collaboration with CAGE Bio Inc. for development of TAGX-0003 for treatment of dermatological autoimmune skin diseases.
TAGX-0003 is an DNA aptamer possessing potent IFN-γantagonistic activity developed by TAGCyx and has already shown effective data in humanized autoimmune skin disease animal model such as alopecia areata when intra-dermally injected.
CAGE bio owns innovative proprietary eutectic ionic liquid formulation technology. Applying CAGE Bio’s formulation technology to TAGX-0003, both parties expect TAGX-0003 possibly penetrating into the skin and will be able to develop it as a non-invasive and efficacious dermatological medicine for skin autoimmune diseases.
Dr. Chizuko Koseki, CEO of TAGCyx said “Collaborating with CAGE bio, we believe our aptamer will become a high value therapeutic option for the patient of autoimmune skin disease, such as alopecia areata and vitiligo. It is a challenge for us to make our Xenoligo® penetrable into skin as it is a mid size oligonucleotide aptamer. We are excited our collaboration with CAGE Bio, as we believe CAGE bio’s eutectic ionic liquid platform will make TAGCyx’ mission possible to contribute to our society by delivering highly effective and safe medicine to many people.”.
Nitin Joshi, CEO of CAGE Bio said “we are excited to partner with TAGCyx to develop value added products to help patients suffering from immune dermatological disorders. Our platform is uniquely positioned to stabilize and deliver macromolecules into the skin which will open doors to treat serious diseases, both large and orphan”.
TAGCyx biotechnologies Inc. (http://tagcyx.com/en/)
TAGCyx, based in Tokyo, Japan, is a biotech company exploiting its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. TAGCyx have invented artificial nucleic acid base-pair technology that enables to produce high affinity and selective DNA aptamers “Xenoligo®”.
Xenoligo® is a trade mark registered by TAGCyx Biotechnolies Inc.
CAGE bio Inc. (https://cagebio.com/)
CAGE Bio, based in San Carlos, CA and Fort Worth, TX, is a clinical stage startup company exploiting its proprietary deep eutectic ionic liquid formulation platform to develop products for dermatology, inflammation, and immunology. CAGE Bio has in-licensed technology developed by a research team led by Prof. Samir Mitragotri from the University of California, Santa Barbara.